Company Overview and News

Aturmaju shares fall on rights issue concerns

KUALA LUMPUR: Aturmaju Resources Bhd fell 3.5% in early trade Tuesday after it announced plan to raise up to RM10mil via rights issue.

Trading ideas: Ideal United, Aturmaju, Diversified Gateway, DBE Gurney

KUALA LUMPUR: JF Apex Research expects Ideal United Bintang International Bhd, Aturmaju Resources Bhd , Diversified Gateway Solutions Bhd and Diversified Gateway Solutions Bhd to be among the stocks to watch.
7181 0131

KLCI to stay lacklustre in line with global markets’ decline

6h theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI is expected to start on a lacklustre note today, in line with the overnight fall at most global markets, as sentiment at the world bourses remains jittery with rising geopolitical tensions amid the simmering US-Sino trade conflict.
7181 6025 7121 0131

Ideal United Bintang, Hovid, Aturmaju, KIP REIT, Berjaya Media, Xian Leng, Diversified Gateway and DBE Gurney

12h theedgemarkets
KUALA LUMPUR (Oct 15): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Oct 16) may include Ideal United Bintang International Bhd, Hovid Bhd, Aturmaju Resources Bhd, KiP REIT, Berjaya Media Bhd, Xian Leng Holdings Bhd, Diversified Gateway Solutions Bhd and DBE Gurney Resources Bhd
7181 9687 6025 7121 0131

KLCI drifts lower, tracks regional markets

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI drifted lower at mid-morning, tracking the lacklustre regional markets.
HLFBF APEXF BRDBF 7090 7181 7036 1082 5681 BATS 4162 1163 5256 5199 5210 4456 3301 0026 7668 HIPEF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...